MREO Stock - Mereo BioPharma Group plc
Unlock GoAI Insights for MREO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $10.00M | N/A | $49.21M | N/A |
| Gross Profit | N/A | $7.43M | $257,442 | $25.04M | $-2,050,485 |
| Gross Margin | N/A | 74.3% | N/A | 50.9% | N/A |
| Operating Income | $-47,364,000 | $-28,416,000 | $-53,667,430 | $-28,255,999.136 | $-48,176,780 |
| Net Income | $-43,253,000 | $-29,466,000 | $-42,121,955 | $17.17M | $-209,829,121 |
| Net Margin | N/A | -294.7% | N/A | 34.9% | N/A |
| EPS | $-0.29 | $-1100.22 | $-1750.35 | $749.65 | $-16503.30 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 27th 2025 | JP Morgan | Initiation | Overweight | $7 |
| December 6th 2024 | Jefferies | Initiation | Buy | $7 |
| June 13th 2024 | Robert W. Baird | Initiation | Outperform | $8 |
| October 13th 2023 | BTIG Research | Resumed | Buy | $4 |
| August 12th 2022 | Cantor Fitzgerald | Initiation | Overweight | $4 |
Earnings History & Surprises
MREOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.00 | $-0.01 | -161.1% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-1.36 | $-7.69 | -465.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.78 | $-0.02 | +97.4% | ✓ BEAT |
Q2 2024 | May 15, 2024 | — | $-0.01 | — | — |
Q1 2024 | Mar 27, 2024 | $-0.02 | $-0.01 | +44.7% | ✓ BEAT |
Q4 2023 | Nov 17, 2023 | — | $-0.01 | — | — |
Q3 2023 | Sep 7, 2023 | $-0.02 | $-0.03 | -37.0% | ✗ MISS |
Q2 2023 | Jun 27, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 28, 2023 | $-0.05 | $-0.03 | +28.9% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.38 | $-0.02 | +95.6% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-0.05 | — | — |
Q2 2022 | Apr 1, 2022 | $-4.50 | $0.00 | +100.0% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.03 | — | — |
Q4 2021 | Nov 8, 2021 | $-2.50 | $0.00 | +100.0% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $0.04 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.03 | — | — |
Latest News
BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
📈 PositiveMereo BioPharma Group Q3 EPS $(0.01) Beats $(0.03) Estimate
📈 PositiveJP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
📈 PositiveMereo BioPharma And āshibio Announce Exclusive Licensing Agreement For Vantictumab In Autosomal Dominant Osteopetrosis Type 2; āshibio Has Exclusive License To Develop And Commercialize Vantictumab Globally, Excluding Europe, Where Mereo Retains Commercial Rights
📈 PositiveFrequently Asked Questions about MREO
What is MREO's current stock price?
What is the analyst price target for MREO?
What sector is Mereo BioPharma Group plc in?
What is MREO's market cap?
Does MREO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MREO for comparison